Secondary hyperparathyroidism is a disease that affects the parathyroid glands, leading to an increased production of parathyroid hormone (PTH) to maintain normal calcium levels in the blood. The disease is caused by an underlying chronic kidney disease in which the phosphorus in the blood is not cleaned by the kidneys. This excess phosphorus in the blood leads to a decline in calcium levels causing secondary hyperparathyroidism. In the early stages of secondary hyperparathyroidism, the PTH levels are high though the calcium levels are low or normal. The high levels of PTH lead to cardiovascular complications, low blood count, abnormal fat and sugar metabolism, weakening of bones, and calciphylaxis. The other causes of secondary hyperparathyroidism include vitamin D deficiency, vitamin D-resistant rickets, high abnormal levels of magnesium, malnutrition, and gastrointestinal malabsorption syndrome.
Growth in prevalence of chronic kidney disease, which is a leading cause of secondary hyperparathyroidism, is one of the primary reasons for the growth of the secondary hyperparathyroidism treatment market. In addition, increase in research activities on the disease and rise in product approvals contribute to the growth of the market. For instance, in 2016, Amgen’s Parsabiv (etelcalcetide) was granted marketing authorization in Europe for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Furthermore, the growing number of products in the pipeline drives the market growth. However, the side effects associated with the secondary hyperparathyroidism treatment such as diarrhea, vomiting, muscle spasm, and decrease in serum calcium might have a negative impact on the market. Furthermore, decrease in the serum calcium levels as a result of the treatment leads to increased risk of heart failure owing to hypotension and decreased myocardial performance.
The secondary hyperparathyroidism treatment market can be segmented based on treatment type, distribution channel, and geography. On the basis of treatment type, the market can be segmented into surgery and drug class. The drug class can be further sub-segmented into vitamin D and derivatives, calcimimetics, and phosphate binders. Among the drug class, calcimimetics are anticipated to record a significant growth owing to their ability to bind to parathyroid cell receptors and decrease the level of calcium in blood serum. Furthermore, the increasing product approvals of calcimimetics contribute to the rapid growth of the segment. On the basis of distribution channel, the market can be segmented into hospital pharmacies and retail pharmacies. The hospital pharmacies segment is anticipated to dominate the market during the forecast period.
Geographically, the secondary hyperparathyroidism treatment market is distributed over North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to record a significant market share of the secondary hyperparathyroidism treatment. This can be attributed to the well-developed health care infrastructure, growth in awareness among people, and favorable reimbursement scenarios. Europe is anticipated to be the trailing next region in the market. However, the market growth in the region is anticipated to be affected owing to the sluggish economic growth. The Asia Pacific market is expected to record a robust CAGR during the forecast period. This growth can be attributed to the significant contribution from the emerging countries such as China and India. The high prevalence of chronic kidney disease in the region further drives the growth of the market.
The leading players operating in the secondary hyperparathyroidism treatment market include Amgen Inc., OPKO Health, Inc., AbbVie Inc., Shire Plc, F. Hoffmann-La Roche AG, Sanofi S.A., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc, KAI Pharmaceuticals, Leo Pharma A/S, and Deltanoid Pharmaceuticals.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.